Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same

A fatty liver disease, non-alcoholic technology, applied in the field of pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease and using the pharmaceutical composition to prevent or treat non-alcoholic fatty liver disease, can solve the problem of C To prevent and treat liver fibrosis or cirrhosis

Inactive Publication Date: 2013-01-16
DONG A PHARMA
View PDF4 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, hepatotoxicity of statins may undesirably lead to elevated blood levels of alanine aminotransferase (Browning J et al., Hepatology 2006, 44:466-471)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
  • Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
  • Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Embodiment 1: the tartrate of compound 1 and sitagliptin phosphate are to high-fat feed-induced Preventive effect of simple steatosis in mice

[0071] In order to investigate the preventive effect of the tartrate salt of Compound 1 (prepared according to the method described in Korean Patent Application No. 2008-0036052) and sitagliptin phosphate on simple steatosis, the following experiments were performed.

[0072] 6-week-old male C57BL / 6 mice were stabilized and then divided into 5 groups. One group was given a standard feed containing 10% fat (trade name: D 12450B, produced by Research Diets), and one group was given a high-fat feed containing 60% fat (trade name: D12492, produced by Research Diets). The remaining three groups were drug-treated groups given a specially formulated drug-mixed feed by mixing a high-fat feed with the drug. For the tartrate salt of compound 1, in order to provide 100 mg / kg and 300 mg / kg (the daily target dose of the tartrate salt of...

Embodiment 2

[0078] Embodiment 2: The tartrate of compound 1 is to the rat simple steatosis induced by high-fat diet sexual healing

[0079] In order to investigate the effect of the tartrate salt of Compound 1 (prepared according to the method described in Korean Patent Application No. 2008-0036052) on simple steatosis, the following experiments were performed.

[0080] 6-week-old male rats (Wistar rats) were stabilized and then divided into 2 groups. The animal groups were given a standard feed containing 10% fat (trade name: D 12450B, produced by Research Diets) and a high-fat feed containing 60% fat (trade name: D12492, produced by Research Diets) for 24 weeks. When the feed consumption was calculated at the 22nd week when the feed was provided, the high-fat feed fed group showed a feed intake of 33.40 g / kg. In order to provide a daily target dose of 10 mg / kg of the tartrate salt of Compound 1, the feed was formulated by mixing a high fat feed with 0.03% by weight of the tartrate ...

Embodiment 3

[0082] Embodiment 3: the tartrate of compound 1, sitagliptin phosphate and vildagliptin are to high fat Diet-induced simple steatosis prevents non-alcoholic fatty liver disease in mice

[0083] In order to investigate the preventive effect of the tartrate salt of Compound 1 on non-alcoholic fatty liver (simple steatosis), the following experiments were performed.

[0084] 7-week-old male C57BL / 6 mice were stabilized and then divided into nine groups (n = 9) based on body weight and blood glucose levels. A vehicle solution (0.5% MC (methylcellulose)) of each feed was orally administered once a day to the standard feed-fed group and the high-fat feed-fed group at a dose of 10 ml / kg, and corresponding to the named groups, To the rest of the group orally administered once a day with the tartrate of Compound 1 at doses of 30, 100 and 300 mg / kg, sitagliptin phosphate at doses of 100 and 300 mg / kg, and vitamin C at doses of 100 mg / kg and 300 mg / kg, respectively. Gliptin mixed wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof.; Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease and a method for preventing or treating fatty liver disease. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) refers to a broad spectrum of diseases, including simple steatosis without inflammation in patients without excessive alcohol consumption, and the progression of simple steatosis caused by liver disease. Nonalcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis of cellular inflammation, and nonalcoholic fatty liver disease is a broader concept than the former term nonalcoholic steatohepatitis (Ludwig J et al., Mayo Clin Proc 1980, 55(7):434-438). [0003] According to the pathological reasons, NAFLD can be divided into primary NAFLD and secondary NAFLD. It is known that primary NAFLD is caused by hyperlipidemia, diabetes, obesity, etc. characteristic of metabolic syndrome, while secondary NAF...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61K31/401A61P1/16A61P1/00
CPCA61K31/495A61K31/4985A61P1/00A61P1/16A61P3/04A61P3/06A61P3/10A61K31/496A61K31/401
Inventor 安国俊梁银京赵恩静蔡洧娜崔圣贤金夏东申昌烈金美庆郭祐宁金兴载孙文虎金舜会
Owner DONG A PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com